Leukaemia & Lymphoma Research’s supports today’s (25 January 2012) decision by the National Institute for Health and Clinical Excellence (NICE) to recommend the extended use of the highly effective monoclonal antibody Rituximab in treating follicular lymphoma.
Ken Campbell, Clinical Information Officer at Leukaemia & Lymphoma Research, said: “We welcome the decision by NICE to recommend rituximab for use in combination with a range of chemotherapy drugs to treat follicular lymphoma. Previously patients with this type of non-Hodgkin lymphoma could only receive Rituximab in combination with a chemotherapy regime of cyclophosphamide, vincristine and prednisolene (CVP).
“This ruling gives more options to doctors to use their best judgement in choosing treatment for patients. Rituximab has been shown to be effective with a range of chemotherapy. Any patient well enough to receive treatment can now be given the drug in combination with chemotherapy options suitable to their individual diagnosis. This decision will help improve quality of life and survival times for patients who did not previously qualify for Rituximab because they were not suitable for CVP treatment.”
Read more about the NICE guidance here.